|
Per clinical trial (b)(6) : on (b)(6) 2016 patient underwent bilateral mastopexy/augmentation/reduction using a full vertical and horizontal t incision.2 pieces of galaflex were used.No concomitant procedures were done.On (b)(6) 2016, erythema/redness, right trifurcation was reported.On (b)(6) 2016, patient had right inferior areola debridement and was treated with medication (keflex, silvadene 1%).Resolved without sequelae on (b)(6) 2016.Review by medical affairs identifies the reported erythema/redness is likely related to the device and serious.
|
|
Based on the information provided, no conclusions can be made.As reported, patient experienced post-op complications of erythema/redness.Medical affairs has assessed the patient¿s postoperative course as being serious and likely related to the study device.Review of the device history records confirmed the device was manufactured to specification.Note: this mdr report is related to a retrospective study conducted to proactively gather real-world evidence on the use and safety of the p4hb product family, including galaflex scaffold, galaflex 3d, and galaflex 3dr. all safety events from the study are adjudicated by the bd medical monitor for an independent assessment of severity and relatedness. in an abundance of caution, events for which relatedness cannot be ruled out are processed for mdr reporting.
|